Slide 1: InMode Profile & Strategy
INMODE PROFILE & STRATEGY NOVEMBER 2025
Slide 2: Safe Harbor Disclaimer
SAFE HARBOR DISCLAIMER • This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future reven
Slide 3: Company Overview
CD COMPANY OVERVIEW
Slide 4: InMode: Who We Are
INMODE: WHO WE ARE 1 Leading global provider of innovative, minimally-invasive aesthetic and wellness solutions, with strong brand recognition Broad radiofrequency (“RF”) based portfolio (capital and consumables) providing specialized aesthetic and wellness solutions to plastic 2 surgeons, dermatolo
Slide 5: InMode Q3 2025: By the Numbers
INMODE Q3 2025: BY THE NUMBERS $0.38 78% $24.5M $93.2M Q3-2025 Non-GAAP Diluted Q3-2025 Q3-2025 Q3-2025 Revenue Non-GAAP Non-GAAP Earning per Share Gross Margin Net Income 12,679 Selling in 10 Patented US Installed Base 88 284 Technologies Across 29,847 Direct Sales Reps Unit Installed Worldwide Cou
Slide 6: The InMode Executive Team
THE INMODE EXECUTIVE TEAM MOSHE MIZRAHY DR. MICHAEL KREINDEL, Ph.D Co-Founder & Chief Executive Officer Co-Founder & Chief Technology Officer • 20 + years industry experience • 20 + years industry experience • Co-Founder; CEO of InMode since its inception • Co-Founder; CTO of InMode since its incept
Slide 7: InMode Global Organization Selling in 88 Countries
INMODE GLOBAL ORGANIZATION SELLING IN 88 COUNTRIES 656 employees worldwide, including 284 direct sales reps and 41 person R&D team AMERICAS EUROPE ISRAEL ASIA • 178 persons direct sales force in the US • Wholly-owned subsidiaries in Spain, • Corporate headquarters • Wholly-owned subsidiaries in Aust
Slide 8: The Evolving Aesthetics Market
THE EVOLVING AESTHETICS MARKET
Slide 9: The Unmet Need in Medical Aesthetics: The Treatment Gap
THE UNMET NEED IN MEDICAL AESTHETICS: THE “ TREATMENT GAP” Significant opportunity for innovative and differentiated minimally-invasive solutions LASER PROCEDURES THE “TREATMENT GAP” PLASTIC SURGERY 40 million procedures annually 2.5 million procedures annually Demographics: 35-60 yrs. old wor
Slide 10: Solution for the Treatment Gap – Evolutionary Progress
SOLUTION FOR THE TREATMENT GAP – EVOLUTIONARY PROGRESS INMODE Traditional laser companies
Slide 11: Aesthetics Industry Undergoing a Paradigm Shift
AESTHETICS INDUSTRY UNDERGOING A PARADIGM SHIFT “Treatment Gap” patients are increasingly looking for solutions that address the shortcomings of laser-based aesthetics and the complexity of full surgery From: Traditional Laser-Based Aesthetics To: Minimally-Invasive/Ablative Aesthetic Surgery • In-o
Slide 12: Who Do We Serve?
WHO DO WE SERVE? InMode’s Major Customers Significant U.S. Market Opportunity (# of Surgically-Trained Physicians) • 100,000+ surgically-trained physicians in the U.S. 45,000 and 200,000+ globally • While not all of these physicians focus on aesthetics, many do perform aesthetic procedures • Interes
Slide 13: InMode Solutions Proprietary Technologies
INMODE SOLUTIONS PROPRIETARY TECHNOLOGIES REFINED TECHNOLOGY • ENHANCED PRECISION • EXCEPTIONAL RESULTS
Slide 14: RFAL - Radiofrequency Assisted Lipo-Coagulation
RFAL - RADIOFREQUENCY ASSISTED LIPO-COAGULATION InMode Proprietary Technology I Soft Tissue Contraction for the face and body results without the large visible scars – the “Holy Grail of Plastic Surgery” RFAL Technology Delivers directional RF energy into the subcutaneous fat. Allows the treatme
Slide 15: Before & After: Body Procedures Using RFAL
BEFORE & AFTER: BODY PROCEDURES USING RFAL “After” results reflect 1 treatment. ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 16: InMode Proprietary Technology II
InMode Proprietary Technology II Advanced technology discharging fractionated radiofrequency (FRF) internally to maximal depths. FDA cleared for soft tissue contraction. Delivers bipolar pulsed RF to new maximal depths of up to 60mm, without damaging the dermis. QuantumRF 25 for body and Qua
Slide 17: QuantumRF 10
QUANTUMRF 10 Six weeks after a single QuantumRF treatment showing quick recovery and minimal downtime. ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 18: Subdermal Fractional RF (FRF)
SUBDERMAL FRACTIONAL RF (FRF) InMode Proprietary Technology III High-quality results with fewer treatments and shorter downtimes than full aesthetic solutions Deep Subdermal Fractional RF (FRF) Delivers bipolar RF energy under the dermis through an array of needle electrodes producing localized he
Slide 19: New FDA Indications
NEW FDA INDICATIONS Soft tissue Tissue Hemostasis Penetration coagulation contraction depth up to 7mm
Slide 20: Morpheus8 Global Awareness & Adoption
MORPHEUS8 GLOBAL AWARENESS & ADOPTION
Slide 21: Face Treatment Subdermal Fractional RF
FACE TREATMENT SUBDERMAL FRACTIONAL RF “After” results reflect 3 treatments 6 weeks apart ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 22: Body Using Deep Subdermal Fractional RF
BODY USING DEEP SUBDERMAL FRACTIONAL RF “After” results reflect 2 treatments 4 weeks apart ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 23: Hands-Free Body Treatment
HANDS-FREE BODY TREATMENT InMode Proprietary Technology IV • Platform supports multiple technologies • Saves time for the operator • Allows increased treatment time and improved efficiency • Reproducible treatment protocol and results • Addresses multiple problems of the body
Slide 24: Multiple Simultaneous Treatments
MULTIPLE SIMULTANEOUS TREATMENTS
Slide 25: Non-Invasive Body Treatment
NON-INVASIVE BODY TREATMENT Evolve: Dr. S. Theodorou & Dr. C. Chia “After” result reflects a series of treatments ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 26: Customized Facial Treatment
CUSTOMIZED FACIAL TREATMENT InMode Proprietary Technology V THE ULTIMATE ALL-IN-ONE FACIAL PLATFORM REDEFINING NON-INVASIVE FACIAL TREATMENTS • The zoom effect, social media, and celebrity culture continue to drive patient demand for sculpted cheeks, chiseled jawlines, and more defined facial featur
Slide 27: FSN Treatment and Block Heating
FSN TREATMENT AND BLOCK HEATING
Slide 28: Define + Morpheus8 Procedure
DEFINE + MORPHEUS8 PROCEDURE Evoke: Dr. R. RohrichPhoto and D.Courtesy: Weir, NP-C Dr. K. Donnay “After” result reflects a series of treatments ___________________________ Note: These are sample results and may not be indicative of actual results.
Slide 29: Ocular Treatments
OCULAR TREATMENTS InMode Proprietary Technology VI Health Canada certified to address the symptoms of dry eye disease (DED) caused by Meibomian Gland Dysfunction (MGD). Intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation. This g
Slide 30: InMode's Existing Portfolio of Technologies
INMODE’S EXISTING PORTFOLIO OF TECHNOLOGIES Since 2010, InMode has launched multiple innovative product platforms
Slide 31: Historical Performance
HISTORICAL PERFORMANCE Revenue / Non-GAAP Net Income ($ in millions) Revenue Non-GAAP Net Income 520.0 492.0 480.0 454.3 440.0 394.9 400.0 357.6 360.0 320.0 280.0 221.5 240.0 206.1 207.5 200.0 156.4 176.3 142.7 136.1 160.0 123.1 126.8 130.2 100.2 106.1 97.9 95.6 93.2 120.0 89.1 80.3 86.4 77.9 80.0 5
Slide 32: InMode Quality Medical Manufacturing
INMODE QUALITY MEDICAL MANUFACTURING
Slide 33: Key Opinion Leaders & Luminaries
KEY OPINION LEADERS & LUMINARIES S. ASTON A. GHAVAMI S. FARHANG A. HOYOS L. CHEUcK R. ROHRICH E. DAYAN M. PEREDO S. NAZARIAN M. KARRAM Podium Presentations | Clinical Trials | Publications |Training | Reference Calls | Media
Slide 34: Leader in Clinical Excellence
LEADER IN CLINICAL EXCELLENCE 100+ Peer Reviewed Publications and Counting “The mean skin surface area reduction was 25.8% in regions treated with radiofrequency “This technology allows precise soft plus SAL at 6 weeks, and increased to 36.4% at tissue modeling at multiple levels to 1 year.” enhance
Slide 35: Consumer Awareness
CONSUMER AWARENESS “4 Fotiowing the birth of my son, | noticed physical changes that couldn't address through my regular routine and diet. | turned to InMode to address those concerns, and Hove the results. 77 - Eva Longoria POPSUGAR. What Is Morpheus8, and Why Are So Many Celebrities Raving About I
Slide 36: Business | Consumer | Industry Recognition
BUSINESS | CONSUMER | INDUSTRY RECOGNITION
Slide 37: Thank You
THANK YOU